Prevention and treatment of cryptosporidiosis in immunocompromised patients
about
Drug Development Against the Major Diarrhea-Causing Parasites of the Small Intestine, Cryptosporidium and GiardiaDrug repurposing and human parasitic protozoan diseasesTravel advice for the immunocompromised traveler: prophylaxis, vaccination, and other preventive measuresCryptosporidium infection in solid organ transplantationAntiparasitic therapySeasonality of Cryptosporidium oocyst detection in surface waters of Meru, Kenya as determined by two isolation methods followed by PCRCryptosporidium and Giardia in Africa: current and future challenges.Clinical significance of enteric protozoa in the immunosuppressed human population.Cryptosporidium-malnutrition interactions: mucosal disruption, cytokines, and TLR signaling in a weaned murine model.Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria boxHigh dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerDiffuse small bowel thickening in AIDS patient--a case report.In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality.Cryptosporidiosis in HIV/AIDS patients in Kenya: clinical features, epidemiology, molecular characterization and antibody responses.Global distribution, public health and clinical impact of the protozoan pathogen cryptosporidiumGuidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theDrug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growthRole of CpSUB1, a subtilisin-like protease, in Cryptosporidium parvum infection in vitro.Antibody responses to the immunodominant Cryptosporidium gp15 antigen and gp15 polymorphisms in a case-control study of cryptosporidiosis in children in Bangladesh.Serum IgG response to Cryptosporidium immunodominant antigen gp15 and polymorphic antigen gp40 in children with cryptosporidiosis in South India.Serum antibody responses to polymorphic Cryptosporidium mucin antigen in Bangladeshi children with cryptosporidiosis.Cases of cryptosporidiosis co-infections in AIDS patients: a correlation between clinical presentation and GP60 subgenotype lineages from aged formalin-fixed stool samples.Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.An apicomplexan ankyrin-repeat histone deacetylase with relatives in photosynthetic eukaryotesEFFICACY OF NITAZOXANIDE AGAINST Toxocara canis: LARVAL RECOVERY AND HUMORAL IMMUNE RESPONSE IN EXPERIMENTALLY INFECTED MICE.Gastrointestinal and nutritional complications of human immunodeficiency virus infectionINTESTINAL AND PULMONARY INFECTION BY Cryptosporidium parvum IN TWO PATIENTS WITH HIV/AIDSIdentification and characterization of Cryptosporidium parvum Clec, a novel C-type lectin domain-containing mucin-like glycoprotein.Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Nitazoxanide: nematicidal mode of action and drug combination studies.Human immune responses in cryptosporidiosis.Cryptosporidiosis in children in the Indian subcontinent.Cryptosporidiosis: environmental, therapeutic, and preventive challenges.A day at the pool.Cryptosporidial diarrhea in an immunocompetent adult: role of nitazoxanide.Childhood cryptosporidiosis: a case report.The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominisEvaluation of multiplex tandem real-time PCR for detection of Cryptosporidium spp., Dientamoeba fragilis, Entamoeba histolytica, and Giardia intestinalis in clinical stool samples.Cryptosporidium parvum glycoprotein gp40 localizes to the sporozoite surface by association with gp15.
P2860
Q26774724-DAEE3DCD-3958-4076-8A33-0F9FC83EC112Q26999453-C4CC5609-A723-44C5-98EF-78D282841A78Q27687760-C6D8EB1D-A44A-4F86-9C52-C652F5E819B8Q28069815-13507986-944D-4F61-86E7-802170EC8B77Q28239164-62C7A32B-D947-4F95-B3C6-0E2F73C9D9F0Q28752063-CEEED69D-8368-49BC-AC8B-21C0B54A6710Q30234730-90D33DB5-B347-4C4D-B440-5E91EC998E35Q30381583-0DC6A9F7-36E8-4F9C-AF1C-D60A2C42D90DQ30423711-A36457E9-FE0F-4E8D-8835-436F2BEFC55AQ30486772-E0ADC652-FA71-453E-A2D2-9C7F33A8980BQ33517055-476CA1D1-FF58-4696-9C61-411AB4868FADQ33650105-683CA53B-0A7A-44AD-A9DD-95C9BC63C7CCQ33732096-CDCC6BA2-E0A2-46DB-8D77-80ACBFAF7618Q33854925-3BCD912A-93B5-414C-85BA-2EF201841D8EQ34015942-0E0BE567-77CC-4674-88F6-D03E6CB12160Q34034600-8F6CFF39-CB3A-4805-8C19-D489384C0C89Q34212799-F096D7C6-5639-4666-AE46-E12D4DED5BE7Q34574121-3823FC4B-1838-4B5F-9676-5518EC8D9891Q34929677-7DFCE023-5062-46DD-9200-1C4FA7C7069CQ35065607-24D5427A-7B47-417C-AEA2-C592AB068A29Q35066352-CD8F48A1-30AD-4C31-AA03-DCDD91F86659Q35186820-0213D44F-87CE-4DCF-B3D4-12A319C54111Q35222537-3FFB36FD-2B91-4890-A9D0-27B24E2AD2C8Q35951126-3AB69538-6E14-4F23-88DA-CEC1EF704A54Q36192352-2EB39F1D-0D9A-406E-A189-44631184A870Q36196130-84383BB7-02C9-46D0-B563-9A8E6B0E45D8Q36233095-D66C5999-AA9F-4FA0-8CB2-D1E7EE01302AQ36720386-19F84A0E-5EC8-41E9-ADF5-D6E20532293BQ37123702-F6E57D1F-2EDB-4FBB-AAF2-A00C70DFEA26Q37180338-26F76FDD-F196-4988-AD7B-AAF0F8BA5CADQ37678601-3A76402C-BB57-421B-9582-6D93915D27B3Q37704368-1B0F2432-D9AB-4571-9725-CFD699303227Q37724830-E2EA567F-FADA-4001-B94B-B05ED778DEC2Q37762488-9ED5490D-91C0-416F-80CF-B5B51B750132Q39719937-3D8EA495-FB2A-4CB6-8D10-753FD9524C8EQ41848301-6F5C3FB5-00A9-46FC-8A14-00960F785F6BQ41976042-C347F5BD-4B40-4985-A76F-772C5EE39807Q41991627-DE2FA394-7D21-417D-A1E4-44F476A41802Q42169383-D1C57ADE-97D8-4DF2-A5D4-163D80256DA7Q42571297-FE10C25F-914C-4CE4-9BF3-036C0AA018B2
P2860
Prevention and treatment of cryptosporidiosis in immunocompromised patients
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@ast
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@en
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@en-gb
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@nl
type
label
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@ast
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@en
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@en-gb
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@nl
prefLabel
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@ast
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@en
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@en-gb
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@nl
P2093
P2860
P3181
P1476
Prevention and treatment of cryptosporidiosis in immunocompromised patients
@en
P2093
Chitra Arumugam
Nuhu Usman
Paul R. Hunter
Sani H Aliyu
P2860
P3181
P356
10.1002/14651858.CD004932.PUB2
P577
2007-01-24T00:00:00Z